• [Articles] Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
    Monday, June 30, 2025 from The Lancet Oncology
    Oestrogen hormone therapy use was inversely associated with young-onset breast cancer, and oestrogen plus progestin hormone therapy was associated with higher young-onset breast cancer incidence among women with intact uterus and...
  • [Correspondence] Bridging tumour classification and treatment
    Monday, June 30, 2025 from The Lancet Oncology
    We read with great interest Jennelle C Hodge and colleagues’ Comment on the WHO Classification of Tumours1 and wish to highlight the crucial need to bridge the growing gap between diagnostic classification and therapeutic access in the...
  • [Correspondence] Considerations for results of the patient-reported outcome analyses of the TALAPRO-2 trial
    Monday, June 30, 2025 from The Lancet Oncology
    Nobuaki Matsubara and colleagues1 and Andre P Fay and colleagues2 are to be congratulated for making the patient perspective an integral part of cancer drug development with patient-reported outcomes from the TALAPRO-2 trial.
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
    Monday, June 30, 2025 from The Lancet Oncology
    The 50-month follow-up of LITESPARK-004, reported by Ramaprasad Srinivasan and colleagues,1 marks a pivotal advance for von Hippel-Lindau disease, a rare syndrome with limited therapies. The findings on belzutifan's durable efficacy,...
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors
    Monday, June 30, 2025 from The Lancet Oncology
    Ramaprasad Srinivasan and colleagues described good oncological outcomes coupled with acceptable toxicity following treatment with the hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan for patients with von Hippel-Lindau...
  • [Correspondence] Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply
    Monday, June 30, 2025 from The Lancet Oncology
    We thank the authors of these Correspondence pieces for their interest in our Article.1
  • [Corrections] Correction to Lancet Oncol 2024; 25: 1614–24
    Monday, June 30, 2025 from The Lancet Oncology
    Hughes T, Harper A, Gupta S, et al. The current and future global burden of cancer among adolescents and young adults: a population-based study. Lancet Oncol 2024; 25: 1614–24—In this Article, figure 3 has been replaced with an updated...
  • [Corrections] Correction to Lancet Oncol 2025; 26: e46–54
    Monday, June 30, 2025 from The Lancet Oncology
    Romero Y, Tittenbrun Z, Trapani D, et al. The changing global landscape of national cancer control plans. Lancet Oncol 2025; 26: e46–54—In this Policy Review, the spelling of Maha Al-Ghafry's name was incorrect in the NCCP Global Review...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 503–15
    Monday, June 30, 2025 from The Lancet Oncology
    Van Gorp T, Moore KN, Konecny GE, et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 571–82
    Monday, June 30, 2025 from The Lancet Oncology
    Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 2025; 26:...
  • [Corrections] Correction to Lancet Oncol 2025; 26: e320–30
    Monday, June 30, 2025 from The Lancet Oncology
    Villarreal-Garza C, Aranda-Gutierrez A, Gonzalez-Sanchez DG, et al. National cancer control plans in Latin America and the Caribbean: challenges and future directions. Lancet Oncol 2025; 26: e320–30—In this Policy Review, the spelling of...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 924–35
    Monday, June 30, 2025 from The Lancet Oncology
    Reddy CL, Sousa C, Atun R. Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational study. Lancet Oncol 2025; 26: 924–35—In this Article, Prof Rifat Atun should have had the additional...
  • [Perspectives] Solutions for tackling the global surgery crisis in west Africa
    Monday, June 30, 2025 from The Lancet Oncology
    The global surgical crisis has become one of the most discussed health topics since the Lancet Commission report published in 2015 because the need is massive, and the consequences are devastating both to countless personal lives and to...
  • [Perspectives] You are her son, not her doctor
    Monday, June 30, 2025 from The Lancet Oncology
    It was by far the most difficult phone call of my life. Absolutely nothing can prepare you for telling your mother that she has stage 4 lung cancer. One does not need to understand the intricacies of cancer staging to feel the gravity of...
  • [Correspondence] Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
    Monday, June 30, 2025 from The Lancet Oncology
    The results of the dose-expansion portion of our multicentre, open-label, phase 1b study evaluating the combination of gedatolisib, a pan-PI3K–mTORC1/2 inhibitor, with palbociclib and endocrine therapy in patients with hormone...
  • [Correspondence] RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
    Monday, June 30, 2025 from The Lancet Oncology
    The RADIOSA phase 2 randomised clinical trial included 102 patients with metachronic oligometastic prostate cancer who were randomly assigned to receive either stereotactic body radiotherapy (SBRT) with 6 months of androgen deprivation...
  • [Correspondence] RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues
    Monday, June 30, 2025 from The Lancet Oncology
    We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed randomised phase 2 study represents an important effort in addressing the role of stereotactic body radiotherapy...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    We read the published Article by Berend J van der Wilk and colleagues reporting the results of the SANO trial with great interest as it reveals many crucial questions regarding the optimal treatment of patients with resectable...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    The validity of the SANO trial hinges on a single premise: the procedure for monitoring complete clinical response is reliable.1 Every patient randomly assigned to surgery was first confirmed to have a complete clinical response by the...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    Despite the obvious interest in an organ preservation strategy for oesophageal cancer, the SANO trial, published in the report by Berend J van der Wilk and colleagues,1 has important limitations, which must be carefully considered in the...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions
    Monday, June 30, 2025 from The Lancet Oncology
    The SANO study by Berend J van der Wilk and colleagues showed non-inferiority of the non-surgical approach if complete clinical response was reached with chemoradiation in patients with resectable oesophageal squamous cell carcinoma.1 We...
  • [Correspondence] SANO trial: innovations, risks, and unanswered questions – Authors' reply
    Monday, June 30, 2025 from The Lancet Oncology
    We thank Brian Housman and Raja Flores, Akhill Kapoor and colleagues, Sheraz R Markar and colleagues, and Ahmet Oruç and colleagues for their interest in the SANO trial. We are pleased to elaborate on their five key issues raised in...
  • [Correspondence] African self-sufficiency in cancer control
    Monday, June 30, 2025 from The Lancet Oncology
    We read with great interest the Lancet Oncology Editorial1 calling for a coordinated global approach to address the growing cancer burden in the face of recent cuts to international aid from high-income nations. While we agree that...
  • [Editorial] Politics and pharma: hurdles in UK science ambitions
    Monday, June 30, 2025 from The Lancet Oncology
    In June, 2025, the UK government announced plans to boost science and technology research and development (R&D) in the country, pledging to invest £86 billion in the sector over the next 4 years. The life sciences sector has been...
  • [Comment] Hormonal therapy for young-onset breast cancer: current understanding and lessons
    Monday, June 30, 2025 from The Lancet Oncology
    The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely investigated in numerous studies and meta-analyses, mainly on hormone replacement therapies for postmenopausal women....
  • Breastfeeding for 6 months could prevent thousands of triple-negative breast cancer cases
    Monday, June 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    More than 10% of new triple-negative breast cancer cases could be avoided if women breastfed or pumped for longer than 6 months, according to results of a retrospective analysis. Between 3,000 and 5,000 diagnoses could be prevented per...
  • Q&A: Women in Medicine Summit will offer attendees a ‘safe space’ to engage in dialogue
    Monday, June 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    This year’s Women in Medicine Summit is being held in Chicago from Sept. 18 to Sept. 20. The summit offers mentorship and networking opportunities, education, workshops, presentations and toolkits while representing over 70 specialties....
  • This AI tracks lung tumors as you breathe — and it might save lives
    Monday, June 30, 2025 from Cancer News -- ScienceDaily
    An AI system called iSeg is reshaping radiation oncology by automatically outlining lung tumors in 3D as they shift with each breath. Trained on scans from nine hospitals, the tool matched expert clinicians, flagged cancer zones some...
  • Women frequently use personal care products that contain cancer-causing ingredients
    Monday, June 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Many Black and Latina women frequently use lotions, soaps, shampoos and other personal care products that contain the carcinogen formaldehyde, or formaldehyde-releasing preservatives, according to study results. More than 50% of...
  • Fire smoke exposure leaves toxic metals and lasting immune changes
    Monday, June 30, 2025 from Lung Cancer News -- ScienceDaily
    Smoke from wildfires and structural fires doesn t just irritate lungs it actually changes your immune system. Harvard scientists found that even healthy people exposed to smoke showed signs of immune system activation, genetic changes...
  • SCOTUS rules USPSTF constitutional, protecting free preventive care, but concerns remain
    Friday, June 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The Supreme Court decided 6-3 to protect no-cost preventive health care today, but major medical organizations warn that the ruling leaves loopholes that could be exploited. The Kennedy v. Braidwood Management Inc. case challenged the...
  • Seeing blood clots before they strike
    Friday, June 27, 2025 from Cancer News -- ScienceDaily
    Researchers have found a way to observe clotting activity in blood as it happens -- without needing invasive procedures. Using a new type of microscope and artificial intelligence (AI), their study shows how platelet clumping can be...
  • Inside a plan to use AI to amplify doubts about the dangers of pollutants
    Friday, June 27, 2025 from Cancer | The Guardian
    Risk analyst Tony Cox’s work has been backed by the chemical lobby, and some health experts are alarmed An industry-backed researcher who has forged a career sowing doubt about the dangers of pollutants is attempting to use artificial...
  • Dexrazoxane mitigates long-term cardiotoxicities of doxorubicin for young patients
    Friday, June 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — Dexrazoxane helped adolescents and young adults with cancer who received doxorubicin chemotherapy have significantly better heart function and structure years after diagnosis, according to findings presented at ASCO Annual...
  • As a carer, I’m not special – but sometimes I need to be reminded how important my role is | Natasha Sholl
    Thursday, June 26, 2025 from Cancer | The Guardian
    When our teenage son was diagnosed with cancer, we joined the 3 million-strong army of unpaid carers in Australia. Now the TV series Dying for Sex gives caregiving the value it deserves When I started watching the Disney+ show Dying for...
  • People dying early of cancer costs UK economy £10.3bn a year, study finds
    Thursday, June 26, 2025 from Cancer | The Guardian
    Cancer Research UK says this is more than any other health condition and 350,000 years of productivity are lost People dying early of cancer costs the UK economy £10.3bn a year, more than any other health condition, a study has revealed....
  • 6-week delay in breast cancer surgery linked to higher risk for death
    Thursday, June 26, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their diagnosis to undergo surgery, according to study results published in Breast Cancer Research. Patients with HR+ or...
  • International medical graduates underrepresented in leadership at NCI-designated centers
    Thursday, June 26, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — International medical graduates are underrepresented in leadership roles at NCI-designated cancer centers, according to study results presented at ASCO Annual Meeting. Researchers also observed stark disparities by gender,...
  • Out-of-pocket costs for bowel prep ‘a travesty’ that could hinder colonoscopy access
    Thursday, June 26, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Out-of-pocket expenses for bowel preparation may limit access to colonoscopy, potentially delaying diagnosis and treatment, according to a study published in Gastroenterology. “To have a test where you can identify a cancer before it...
  • Senators question CDC nominee Monarez, including about vaccines
    Wednesday, June 25, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Senators questioned Susan Monarez, PhD, about a range of topics Wednesday during a hearing to assess her nomination to be the next director of the CDC. Monarez expressed some support for HHS Secretary Robert F. Kennedy Jr.’s changes at...
  • Income, education have significant impact on patients with HIV receiving cancer treatment
    Wednesday, June 25, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    More than 15% of individuals living with HIV and cancer have not received recommended first-line cancer therapy, according to results of a retrospective analysis. Among patients with HIV and cancer, those who lived in the lowest...
  • Q&A: Most people unaware of testicular cancer risk in young men
    Wednesday, June 25, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In a recent survey from The Ohio State University Comprehensive Cancer Center, only 13% of adults said testicular cancer is most common among men aged younger than 40 years. However, testicular cancer — which affects about 10,000...
  • Navigational bronchoscopy similar to CT-guided biopsy in lung nodule diagnostic accuracy
    Wednesday, June 25, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    SAN FRANCISCO — Navigational bronchoscopy was noninferior to CT-guided biopsy when assessing diagnostic accuracy in patients with lung nodules, according to findings published in The New England Journal of Medicine. Notably,...
  • Inside the tumor: AI cracks five hidden cell types to stop cancer’s comeback
    Wednesday, June 25, 2025 from Cancer News -- ScienceDaily
    A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner diversity. This insight could transform how we treat cancer, enabling more personalized therapies that tackle every...
  • The pleasure prescription: Why more sex means less menopause pain
    Wednesday, June 25, 2025 from Cancer News -- ScienceDaily
    Keeping sex on the schedule may be its own menopause medicine: among 900 women aged 40-79, those active in the last three months reported far less dryness, pain, and irritation, while orgasm and overall satisfaction stayed rock-solid...
  • VIDEO: New concurrent treatment shows benefit in vulvar cancer
    Tuesday, June 24, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab. Patients who underwent treatment with...
  • VIDEO: Pembrolizumab aids in the treatment of high-risk locally advanced cervical cancer
    Tuesday, June 24, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting. The ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial evaluated...
  • VIDEO: Metformin 'expands options' in endometrial cancer treatment
    Tuesday, June 24, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new research on adding metformin to letrozole/abemaciclib for the treatment of estrogen receptor-positive, recurrent endometrial cancer. The data presented at ASCO Annual...
  • Yelling, cursing, spitting, threats: Incivility toward clinicians a real danger
    Tuesday, June 24, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    “Push through.” Noelle K. LoConte, MD, FASCO, repeated that message to herself over and over again. The clinic had limited staff due to a national holiday, and LoConte, associate professor in the division of hematology, medical oncology...
  • ‘Don’t forget about the rectum’ when performing colonoscopy
    Tuesday, June 24, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Rectal location and timing of diagnosis had minimal impact on cancer-specific and all-cause mortality rates for patients with postcolonoscopy colorectal cancer, according to a cohort study published in JAMA Network Open. Studies often...
  • Powered by Feed Informer